Limited Time Offer
Get $1000 towards your
first investment
Start investing in private markets with Linqto – your access to disruptive startups and pre-IPO companies.
*Terms and conditions apply. See details
CARGO Therapeutics, a clinical-stage biotechnology company focused on developing next-generation CAR T-cell therapies for cancer treatment, has successfully completed its initial public offering (IPO). The company, founded in 2021 and based in San Carlos, California, priced its IPO at $15 per share, offering 18.75 million shares to raise approximately $281.3 million. CARGO's common stock began trading on the Nasdaq Global Select Market under the ticker symbol "CRGX" on November 10, 2023, opening at $15.45 per share.
The company's primary focus is on engineering CAR T-cell therapies designed to overcome resistance and improve access to potentially curative treatments for a wider range of cancer patients. CARGO's lead program, CRG-022, is currently being evaluated in a potentially pivotal Phase 2 clinical trial for patients with large B-cell lymphoma whose disease has relapsed or was refractory to CD19 CAR T-cell therapy.
CARGO Therapeutics' successful IPO demonstrates investor confidence in the company's innovative approach to cancer treatment and its potential to address unmet medical needs. The funds raised through the offering are expected to support the company's ongoing research and development efforts, including the advancement of its lead program and expansion of its pipeline.
The IPO was led by joint book-running managers J.P. Morgan, Jefferies, TD Cowen, and Truist Securities. CARGO has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
As CARGO Therapeutics transitions to a publicly traded company, investors and industry observers will likely monitor its progress in clinical trials, potential partnerships, and advancements in its proprietary cell engineering platform technologies. The company's performance in the public market may also serve as an indicator of investor sentiment towards the broader biotechnology sector, particularly in the field of cell therapies for cancer treatment.
Get $1000 towards your
first investment
*Terms and conditions apply. See details
While CARGO Therapeutics' IPO prospects remain uncertain, investors eager to gain exposure to innovative biotech companies don't have to wait. At Linqto, we offer members access to interests in promising pre-IPO private companies, including potential leaders in the biotechnology sector. Our platform allows you to diversify your portfolio with lower minimum investments, potentially benefiting from the growth of emerging healthcare innovators before they go public.
*These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO. The information provided above is based on current online discussions and is not intended as investment advice. Linqto does not endorse or guarantee the accuracy of this information, and we strongly recommend conducting your own research or consulting with a professional advisor before making any investment decisions. Linqto cannot be held liable for any investment outcomes resulting from the use of this information.
